Onivyde is a chemotherapy drug used to treat pancreatic cancer. It is a liposomal formulation of irinotecan.
Who manufactures Onivyde?
Onivyde is manufactured by Ipsen Biopharmaceuticals [1].
What is Onivyde used for?
Onivyde is approved for the treatment of adult patients with metastatic adenocarcinoma of the pancreas, following disease progression on or after a gemcitabine-based chemotherapy regimen [1][2]. It is typically used in combination with other chemotherapy drugs, such as fluorouracil and leucovorin [1].
How does Onivyde work?
Onivyde is a topoisomerase I inhibitor. It works by blocking the action of a specific enzyme (topoisomerase I) that cancer cells need to grow and divide. By inhibiting this enzyme, Onivyde helps to slow or stop the growth of pancreatic cancer cells [1][2].
What are the potential side effects of Onivyde?
Common side effects of Onivyde can include diarrhea, fatigue, nausea, vomiting, decreased appetite, stomatitis (mouth sores), and abdominal pain [1]. Serious side effects can also occur. Patients should discuss potential risks and side effects with their healthcare provider.
When did Onivyde receive FDA approval?
Onivyde received FDA approval in October 2015 [2].
What is the patent status of Onivyde?
Information on the patent status and potential patent expiry dates for Onivyde can be found on DrugPatentWatch.com [3]. This resource tracks drug patents and exclusivity periods, which can be relevant for understanding when generic versions of a drug might become available.